BioSpace News Archive

CRISPR Therapeutics today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer, will present at the Chardan Genetic Medicines Conference on Tuesday, October 9, 2018 at 11:30 am ET.

Arjuna rebranding its all-natural turmeric extract

Focused on Fresh Food Access and Nutrition

Assembly Biosciences, Inc. today announced that the company will have an oral presentation of the full data set from the Phase 1b study of ABI-H0731 at the upcoming American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The Liver Meeting®), being held November 9-13 in San Francisco.

Aclaris Therapeutics, Inc. today announced that on October 1, 2018 the Compensation Committee of Aclaris’ Board of Directors granted 1 non-qualified stock option award to purchase 7,000 shares of its common stock to one new employee and 4 restricted stock unit awards covering an aggregate of 6,900 shares of its common stock to 4 new employees under the Aclaris 2017 Inducement Plan.

As a company dedicated to expediting research related to the treatment and prevention of Alzheimer’s Disease, Cognitive Clinical Trials (CCT) is fundamentally changing the way these types of studies are performed.

Starting today, California doctors will have to check a patient’s prescription history before prescribing addictive opioids and other controlled substances. The legislation is the culmination of a years-long fight by families impacted by opioid abuse to mandate doctors consult a state prescription database in order to reduce opioid overprescribing and save lives.

The Georgia Power Foundation recently completed a three-year investment of $1 million to Children’s Healthcare of Atlanta’s newly-opened Advanced Pediatrics Center. The Georgia Power Foundation is a non-profit 501(c)(3) organization and the third-largest corporate giving foundation in Georgia.

Dave Herman, Chairman of the American Kratom Association, strongly denounced the action by the State Board of Pharmacy on October 1, 2018 to commence the process to schedule kratom as a Schedule I controlled substance in Ohio.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today further progress on the Company’s platform efforts in extrahepatic delivery of novel siRNA conjugates, including central nervous system (CNS) and ocular delivery in rat and non-human primates (NHPs).